Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 5/20 | 0.38 |
| ▸ | RHEB | Q15382 | 8/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7161852 | 0.74 | FLT3 (0.52) | LOXL2RHEBSIRT1 | |
| SCHEMBL3578511 | 0.73 | CYP2A6 (0.53) | LOXL2RHEBSIRT1F2BCHE | |
| SCHEMBL11865173 | 0.73 | LOXL2 (0.68) | LOXL2SMN1; SMN2 | |
| SCHEMBL12715335 | 0.73 | CYP2A6 (0.53) | MAOAMAOBSMN1; SMN2 | |
| SCHEMBL5100201 | 0.73 | CYP19A1 (0.47) | LOXL2RHEBSIRT1 | |
| SCHEMBL4740651 | 0.73 | LOXL2 (0.68) | LOXL2RHEBSIRT1SMN1; SMN2 | |
| SCHEMBL10300662 | 0.72 | ALOX15 (0.43) | SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL10300658 | 0.71 | SMAD3 (0.60) | — | |
| SCHEMBL11710173 | 0.70 | KDM4E (0.47) | LOXL2RHEB | |
| SCHEMBL29777912 | 0.70 | LOXL2 (0.64) | LOXL2MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217028-B2 | 1,2,4-oxadiazole indole compounds | GLAXO GROUP LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| US-20110086839-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-04-14 | — | — | US | disclosed |
| US-20100029729-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-20100010053-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029729-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | LOXL2 1530/4885RHEB 1180/4885SIRT1 797/4885 |
| US-20100010053-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | LOXL2 1530/4885RHEB 1180/4885SIRT1 797/4885 |
| US-20110086839-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | LOXL2 1530/4885RHEB 1180/4885SIRT1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.